SCHEMBL3982706

SCHEMBL3982706

Cc1ccc(S(=O)(=O)Nc2ccc3cc[nH]c3c2C(=O)O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 1/20 0.53
PTPN2 P17706 1/20 0.53
PTPN1 P18031 1/20 0.53
PTPRB P23467 1/20 0.53
PTPRE P23469 1/20 0.53
PTPN6 P29350 1/20 0.53
POLB P06746 1/20 0.53
APEX1 P27695 1/20 0.53
RECQL P46063 1/20 0.53
CASP6 P55212 1/20 0.53
CTDSP1 Q9GZU7 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ESR1 P03372 1/20 0.50
CYP19A1 P11511 1/20 0.50
METAP2 P50579 10/20 0.49
METAP1 P53582 1/20 0.49
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982699 0.88 METAP2 (0.63) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3988437 0.88 METAP2 (0.62) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3985610 0.88 PTPRC (0.53) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3982737 0.87 ESR1 (0.53) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3982247 0.86 PTPRC (0.49) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3982513 0.79 METAP2 (0.49) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL2367682 0.78 NR3C1 (0.64) POLBTDP1L3MBTL1ESR1CYP19A1
SCHEMBL3984291 0.77 METAP2 (0.82) POLBAPEX1RECQLCASP6CTDSP1
SCHEMBL3984731 0.75 METAP2 (0.55) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3061760 0.74 NR3C1 (0.56) PTPN1RECQLKEAP1CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP PTPRC 2454/4885PTPN2 964/4885PTPN1 2479/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP PTPRC 2454/4885PTPN2 964/4885PTPN1 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.